IDXG — Interpace Biosciences Share News
0.000.00%
Last trade - 00:00- $29.92m
- $27.23m
- $38.73m
Brief: Interpace Biosciences Announces Impending Delisting From Nasdaq
Brief: Interpace Biosciences Announces Path Forward In Letter To Shareholders
Brief: Interpace Biosciences Announces CFO Leadership Transition
Brief: Interpace Biosciences Announces License Agreement With Rutgers University And Mass General Hospital
Brief: Interpace Biosciences Q3 Revenue $8.2 Million Versus Refinitiv Ibes Estimate Of $7.6 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:45 PM
Brief: Interpace Biosciences - Jack Stover To Retire As President And CEO, Thomas Burnell Appointed As Successor
Brief: Interpace Biosciences Receives Nasdaq Deficiency Notice Due To Delayed Filing Of Form 10-Q
Brief: Interpace Biosciences Files Non-Timely 10-Q With U.S. SEC
Interpace Biosciences: Up on positive data on thyroid cancer tests
Brief: Interpace Biosciences Announces Results Of Seminal Clinical Validation Study For Thyroid Assays
Brief: Interpace Biosciences - H.C. Wainwright Cuts Price Target To $10 From $11
Interpace Biosciences: Falls as Q2 rev misses estimates due to COVID-19
Brief: Interpace Biosciences Reports Q2 2020 Results
U.S. STOCKS ON THE MOVE-Twitter, Caterpillar, Wells Fargo, Restaurant Brands
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Boeing, Wells Fargo, Goldman Sachs
Interpace Biosciences rises as probe finds no evidence of illegal acts
Brief: Interpace Biosciences Says Investigation By Audit Committee Finds No Evidence Of Any "Illegal Acts"
Brief: Interpace Biosciences Receives Nasdaq Deficiency Notice Due To Delayed Filing Of Form 10-Q